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A 43-year-old woman with an associated history of gynecological pathology and
breast cancer with only one cryopreserved embryo wished to be a mother.
Several factors that influenced the success of the pregnancy in this case were
analyzed. Favorable factors included: triple positive breast cancer [positive
hormone receptors and positive human epidermal growth factor receptor 2],
which is more hormosensitive and chemosensitive; absence of metastasis; correct
endometrium preparation; and the patient’s optimistic attitude and strict health
habits. In contrast, the factors against success were: breast cancer; adjuvant breast
cancer therapy gonadotoxicity; the age of the patient (> 40-year-old);
endometriosis; ovarian cyst; hydrosalpinx; submucosal fibroids and the
respective associated surgery done for the above-mentioned pathology (all
resolved prior to the embryo transfer); and a low quantity of ovules (low ovarian
reserve) after ovarian stimulation. This is a very special clinical case of a patient
with theoretically low pregnancy success probability due to the consecutive
accumulation of gynecological and oncological pathologies, who nonetheless
became pregnant and delivered a full-term infant and was able to provide
adequate breastfeeding.
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Core tip: Considering age, endometriosis, a hyperplastic endometrium, the presence of
myomas, amenorrhea, breast cancer, chemo- and radiotherapy and in vitro fertilization
with a single cryopreserved embryo, the likelihood of a successful pregnancy was low.
This case report details how a 43-year-old woman was able to overcome these negative
aspects and become the mother of a healthy baby.
Citation: Garrido-Marín M, Argacha PM, Fernández L, Molfino F, Martínez-Soler F,
Tortosa A, Gimenez-Bonafé P. Full-term pregnancy in breast cancer survivor with





There is a growing trend of longer postponement of first pregnancy from age 30 to 40.
This tendency may be the result of socioeconomic factors (e.g.,  level of education,
economic dependence on parents, employment instability, lack of a stable partner,
etc.), and it has been reported to be correlated with a simultaneous increase in the
incidence  of  breast  cancer  in  women  who  have  not  completed  their  families[1].
Currently, nearly 25% of women diagnosed with breast cancer are premenopausal[2];
yet no clear recommendations are available for counselling this population on the
safety of becoming pregnant after breast cancer treatment[3].
Breast cancer accounts for one-third of all  neoplasms seen in reproductive-age
women; it is the most commonly diagnosed cancer for this age group[4]. Among the
tens of thousands of women affected each year, most are candidates for chemotherapy
treatment. The most commonly used adjuvant drug treatment regimens involve a
combination of chemotherapy and hormone therapy. Although this approach has
improved both disease-free survival and overall survival rates in young breast cancer
patients[5],  the agents are well-known for their negative impact on fertility due to
gonadotoxicity, which may even lead to premature ovarian failure[6].  Therefore, a
diagnosis  of  breast  cancer  in  a  young  woman  represents  a  threat  to  fertility.
Oncofertility counseling is of great importance in this regard[7]. These cases should be
managed in a multi-disciplinary manner, involving different health care specialists -
oncologists, breast surgeons, gynecologists, reproductive specialists, breast nurses,
psychologists - with the aim of ensuring that an educated team can keep up with the
progress  of  fertility  preservation  knowledge[8].  Providing  consultation  with  a
reproductive specialist and appropriate information on fertility preservation for these
women should be an essential component of their supportive care[9].
The offspring of patients who became pregnant after completion of chemotherapy
have shown no adverse  effects  or  congenital  anomalies  from the  treatment,  but
sometimes high rates of miscarriage (29%) and premature deliveries with low birth
weight (40%) have been demonstrated[1]. Thus, it is important to offer early referral to
a reproductive specialist to those patients at risk of infertility who are interested in
fertility preservation.
There have been recent advances in the field of fertility preservation in young
women undergoing breast cancer therapy that have allowed many of these breast
cancer survivors to have children in the future. The most common option is embryo
and oocyte cryopreservation (providing a pregnancy rate of 25%-35%), even though
the suitable strategy to be chosen depends also on age, type of chemotherapy, partner
status, and the patient’s motivation. Once oocytes are removed, women undergo in
vitro fertilization (IVF). The IVF process involves stimulation of multiple follicles and
eggs for development (ovarian induction with synthetic gonadotropins), transvaginal
ultrasound-guided oocyte retrieval, fertilization of the eggs in the laboratory, and,
finally, embryo transfer to the uterus, limiting the number of embryo transfers to
maximum of two or three to avoid multiple gestations (which is the most frequent
complication  of  this  procedure)[10].  The  most  serious  complication  after  ovarian
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stimulation  is  ovarian  hyper-stimulation  syndrome  (characterized  by  ovarian
enlargement  due  to  multiple  ovarian  cysts  and  an  acute  fluid  shift  into  the
extravascular space)[11].
Broadly speaking, we can say that the chance of giving birth after one IVF cycle is
approximately 20%-25% in women less than 35 years old, 15%-20% for those 35-39,
and 6%-10% for those over 40[12]. Therefore, the age of the patient is one of the most
influential factors in assisted reproductive outcomes. Nowadays, there are also other
strategies for fertility preservation, some still experimental, such as ovarian tissue
cryopreservation and ovarian suppression with gonadotrophin-releasing hormone
agonists (GnRHa) during chemotherapy[7].
As to adjuvant radiotherapy in breast cancer, it has been shown to have no impact
on the rate or clinical outcome of pregnancy, and no anatomical defects have been
observed in the offspring[13]. Nevertheless, diminished lactation from the irradiated
breast has been reported in those women who underwent radiotherapy following
breast-conserving surgery, presumably due to atrophy of the breast lobules[14].
The following case is interesting because it is about a 43-year-old woman with an
associated history of gynecological pathology, including ovarian cysts, endometriosis,
hyperplastic endometrium, hydrosalpinx, myomas, and amenorrhea. On top of such
negative factors for motherhood, she developed breast cancer (pT1bpN1a, stage IIA),
and  after  chemo-  and  radiotherapy,  she  became  pregnant  following  fertility
preservation of a single cryopreserved embryo. After just one IVF cycle, she delivered
a full-term infant with adequate breastfeeding.
CASE REPORT
The patient  is  a  Caucasian woman born in 1972,  middle class,  with a  university
degree, a base body mass index of 19 kg/m² and strictly healthy hygienic-dietary
lifestyle without unhealthy habits,  and no relevant clinical  family history.  She is
currently premenopausal, with regular periods and a personal history of laparoscopy
due to endometriosis (endometrioma in the left ovary) at age 29. To facilitate visual
understanding of the case, the chronologically ordered medical history constructed
from  the  patient’s  reporting  and  the  information  from  three  medical  centers  is
presented in Figure 1. The patient has private health insurance, so she had no problem
attending any of the three centers.
In July 2011, she went to an initial gynecological examination visit at the Hospital
General de Catalunya due to self-palpation of a superior-external quadrant lump in
the right breast, where a 1 cm mammary nodule compatible with a fibroadenoma was
clinically evidenced. A mammography exam and a breast ultrasound were requested.
These  revealed  a  10  mm  ×  10  mm  nodule  with  radiological  signs  of  suspected
malignancy (Figure 2). Consequently, a targeted biopsy was performed evidencing a
human epidermal growth factor receptor 2 (HER2)-positive hormone-dependent (80%
estrogenic  receptors,  70% progestational  receptors)  CD56  (marker  for  detecting
neuroendocrine differentiation) negative high-grade invasive ductal carcinoma. In the
gynecological  visit,  a  transvaginal  ultrasound  was  also  performed  showing  an
anechoic cystic image of 39 mm diameter in the right adnexal area compatible with a
simple ovarian cyst versus follicular cyst (Figure 3); the rest of the exploration was
anodyne.  Tumor  markers  were  studied  as  well  with  a  CA-125  of  82.2  U/mL
(carbohydrate antigen 125; it has been associated mainly with ovarian cancer when
values are > 35 U/mL but also with other tumors such as breast cancer), with the rest
of the markers normal. Subsequently, a new transvaginal ultrasound was performed
evidencing a  persistence  of  a  5  cm anechoic  cyst  and diagnosing a  38  mm right
hydrosalpinx (Figure 4).
In September 2011, the patient underwent a lumpectomy with a sentinel lymph
node dissection at the Corporació Sanitària Parc Taulí, which confirmed the histologic
diagnosis of high grade (III) invasive ductal carcinoma with two axillary sentinel
lymph nodes affected, classifying the tumor as pT1bpN1a, stage IIA.
With these results, staging was completed with a right axillary lymphadenectomy,
without evidence of other affected lymph nodes. Thus, the patient was a candidate to
receive adjuvant treatment with chemotherapy, radiotherapy, and hormone therapy
for 5 years. In addition, the ovarian cyst disappeared, although the hydrosalpinx,
measuring 33 mm, persisted.
Before starting the treatment, oocyte preservation was carried out after ovarian
stimulation treatment because of the patient’s desire for maternity. The patient started
medication with Letrozole (Femara®)  Protocol (2.5 mg/daily administration, oral
route) and 225 mg of recombinant follicle-stimulating hormone (rFSH) (225 UI daily)
for 10 d. Four follicles developed in the right ovary, but during the pickup it was
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Figure 1
Figure 1  Chronological axis of the patient’s medical history.
found that they were empty. Two ovules that developed in the contralateral ovary,
harder to reach, were extracted in a puncture performed on November 4, 2011 at the
Cefer Institute, and after IVF, only a single day 3 embryo (type A) was available for
freezing.
The patient started adjuvant treatment with chemotherapy following a scheme
based on Epirubicin 90 mg/m2 and Cyclophosphamide 600 mg/m2 every 21 d up to
four  cycles,  followed by Docetaxel  75  mg/m2  and Trastuzumab every 21  d.  She
completed four cycles with good patient tolerance.
In May 2012, the patient started hormone therapy with Tamoxifen 20 mg daily for 5
years, followed by subcutaneous Trastuzumab 600 mg every 3 wk until completing 1
year of treatment. Next, she received radiotherapy (complementing breast conserving
surgery) with a total dose of 66 Gy (2 Gy/fraction, 5 d/wk) followed by a boost of 16
Gy over the surgical site, ending in June 2012.
In December 2013,  she ended treatment  with Tamoxifen due to  her  desire  for
pregnancy, considering that this drug could hinder correct embryo implantation. In
total,  the  patient  underwent  eight  sessions  of  chemotherapy,  18  sessions  of
monoclonal antibodies (Trastuzumab), 33 sessions of radiotherapy, and 2 years of
hormone therapy.
At the end of 2014, her oncologist approved transfer of the single cryopreserved
embryo.  Prior  to  this,  an  ultrasound was  requested  that  showed a  hyperplastic
endometrium and the hydrosalpinx, so doctors decided to carry out a hysteroscopy
with  uterine  cavity  dilation  and  curettage,  and  laparoscopic  surgery  for
exeresis/occlusion of the affected fallopian tube.
In January 2015, a diagnostic hysteroscopy showed two small submucosal myomas,
for which the patient underwent right salpingectomy and hysteroscopic myomectomy
to facilitate a potential pregnancy. Having reached this point, the patient was ready to
begin  the  embryo  transfer.  However,  the  patient  began  having  menstrual  cycle
alterations (amenorrhea), so in June 2015 she started combined oral contraception
with Suavuret® (Fix combination of Desogestrel 0.15 mg and 0.02 mg EthinylEstradiol,
daily) for 18 d to regulate her menstrual cycle.
To prepare the uterine endometrium before embryo transfer and to maintain the
pregnancy,  on  July  15  she  started  treatment  with  Progynova®  4  mg/d for  3  mo
(equivalent to Estradiol Valerate; standard-dose is 6 mg/d, but due to low body mass
index, the dose was lowered). Endometrium was correctly prepared, so the transfer
was  carried  out  on  August  3  (when the  patient  was  43  years  old)  using  an  IVF
reproduction technique with the vitrified embryo from the age of 39 (type A embryo
transfer, with A being the best quality for an embryo to be transferred, B not as good,
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Figure 2
Figure 2  Mammary ultrasound image. Asterisk showing solid tumour, badly defined, irregular and blurry borders
with light posterior shadow. Signs of malignancy on ultrasound.
C poor quality, and D the worst) (Figure 5). On August 17, the biochemical pregnancy
test result was positive [human chorionic gonadotropin was 568 IU]. On the 25th of the
same month, the patient underwent her first  gestational ultrasound showing the
gestational  sac  with  a  sketch  of  vitelline  vesicle.  On  September  8,  at  wk  7  of
pregnancy, fetal heartbeat was positive, so the patient was referred to the obstetrician.
Regular controls made by the obstetrician showed a correctly developing pregnancy
(Figure 6).
Pregnancy was completed without  complications and with a  vaginal  delivery
(assisted  Thierry’s  spatulas)  in  April  2016,  with  a  healthy  girl  born  (full  term
pregnancy at wk 37, 2800 kg weight, and 46.5 cm length). Puerperium was normal,
including 9 mo of exclusive breastfeeding. The last oncological control was in January
2017, without evidence of disease.
DISCUSSION
Hormone-dependent carcinomas, such as breast cancer,  express estrogen and/or
progesterone receptors  and are the most  hormone-sensitive tumors (response to
treatment is 55% in tumors with positive hormone receptors and < 10% in tumors
without them). Hormone therapy is very useful, especially in premenopausal women,
so in this clinical case our patient was a candidate to receive Tamoxifen. This drug
also has beneficial effects on the cardiovascular and skeletal systems (it acts as an
estrogen receptor antagonist in the mammary glands but as an agonist on endometrial
and bone tissue).  Nevertheless,  Tamoxifen has  relevant  side effects  that  include
thromboembolism, ocular toxicity, and even endometrial alterations (endometrial
carcinoma)[15].  Recently,  aromatase inhibitor drugs (such as Letrozole) have been
developed, which are basically used in postmenopausal women because they prevent
synthesis  of  estrogen  from  the  adrenal  gland  (the  main  source  of  estrogen  in
postmenopausal women)[16]. Compared to Tamoxifen, aromatase inhibitors induce
fewer uterine cancers and thrombotic phenomena, but they increase the risk of sexual
dysfunction, arthralgia, osteoporosis, and cardiocirculatory events[17].
Another  relevant  aspect  is  the  presence  of  HER2  gene  overexpression.  It  is
important to determine whether a breast cancer is positive for HER2 or not, because
nowadays there are targeted therapies[18] for this cancer type using HER2 antagonist
drugs, such as Trastuzumab (the first anti-HER2 antibody). Only about 15%-20% of all
breast cancer patients are positive for HER2[19]; that is to say, these are cancers that
have this oncogene amplified, and, in approximately 20% of HER2 cases, tumors
present hormone receptors too. Even so, this subtype of breast cancer tends to have
fairly high cell proliferation rates (measured by the percentage of ki-67), which is the
reason why these  cancers  tend to  be  more aggressive  than tumors  that  are  only
hormone-dependent. Moreover, they are often more undifferentiated (grade 3) and
present  ductal  invasion more frequently than tumors without overexpression of
HER2. For this reason, Trastuzumab has had an enormous impact on the prognosis of
the  presence  of  HER2  in  breast  cancer  (regardless  of  tumor  size,  lymph  node
involvement,  presence  of  hormone receptors,  and age  of  the  patient)[20],  since  it
improves the survival rate in both advanced and localized disease, and its inclusion in
adjuvant chemotherapy reduces relapses by 50%. Over the years, multiple HER2-
targeting drugs have entered clinical practice, for the curative as well as the metastatic
situation. Nowadays, there are several advances in treatment of these patients, and
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Figure 3
Figure 3  Transvaginal gynecological ultrasound. Asterisk shows ovarian cystic tumour containing clear liquid,
well-defined borders, and smooth internal walls, suggesting serous ovarian cyst.
new drugs have been developed such as Lapatinib, T-DM1 (Trastuzumab-Emtansina),
and Pertuzumab[18].
Regarding breast cancer treatment in general and its relation to potential infertility,
it is important to mention that the main risk comes from the chemotherapy regimens
used in these patients. It is well known that breast surgery, radiotherapy (which is
mandatory to complete organ preservation surgery), and lymphadenectomy do not
affect  conception  ability,  but  lymphadenectomy  is  the  main  cause  of  chronic
morbidity in breast surgery. Regarding chemotherapy, the current preference is to
administer monotherapy-based regimens or sequential two-drug therapy. For patients
who are positive for HER2, the most commonly used regimen is anthracycline +
Cyclophosphamide followed by a taxane + Trastuzumab. It is important to highlight
the potential cardiotoxicity of both Trastuzumab and Epirubicin (the anthracycline
used  in  our  patient),  so  in  this  case  strict  control  of  cardiovascular  function  is
necessary. In reference to the agents commonly used for breast cancer, alkylating
agents (such as Cyclophosphamide) are those with the highest gonadotoxic potential
risk; Epirubicin can cause fertility problems in 10% of cases (it affects men as well as
women),  and taxanes can cause intermediate ovarian damage[21].  Moreover,  both
hormone therapy and some chemotherapeutic agents have potential teratogenic risk,
so the most widely accepted recommendation is to avoid pregnancy for a minimum of
2 years after completing cancer treatment[22]. This further compromises the chance of
future biological childbirth by pushing conception attempts to the later stages of a
woman’s reproductive lifetime.
In addition to breast cancer, the patient also had other pregnancy-impeding factors,
such as endometriosis, an ovarian cyst, hydrosalpinx, submucosal myomas, and their
associated surgeries,  all  previously resolved before embryo transfer.  Our patient
underwent laparoscopic treatment of endometriosis.  It  has been reported that in
women with minimal, mild, or severe endometriosis, surgical excision or ablation of
endometriosis is recommended as a first line, with doubling of the pregnancy rate[23].
Concerning  hydrosalpinx,  there  are  cases  where  unilateral  salpingectomy  for
hydrosalpinx  in  the  presence  of  a  contralateral  healthy  tube  could  result  in
spontaneous  pregnancy[24].  Regarding  myomas,  it  is  worth  mentioning  that  the
number  of  myomas  removed during  myomectomy significantly  affects  fertility:
women with > six myomas removed are less likely to become pregnant, more likely to
require fertility treatment, and less likely to have a term birth when compared with
women with less than six myomas removed, as was the case with our patient, from
whom only two myomas were removed[25]. Moreover, it is important to highlight the
age of the patient (over 40-years-old). It should be remembered that females are born
with a maximum number of oogonia, and these will undergo apoptosis throughout
life. To get an idea of this process, we find about 2 million oogonia at birth, and at the
beginning of puberty there are only about 400000 left. Therefore, the age of the patient
conditions  her  low  ovarian  reserve,  making  a  successful  pregnancy  even  more
difficult.
Another factor against successful pregnancy is the low number of ovules produced
by a patient after stimulation with Femara® Protocol and rFSH. This protocol is based
on ovarian stimulation with Letrozole (an aromatase inhibitor),  which produces
estrogen  suppression  both  peripherally  and  intratumorally.  Negative  feedback
produced by estrogens on the hypothalamic-pituitary-gonadal axis is diminished
because of its synthesis reduction, increasing gonadotropin release (FSH increases and
ovulation  is  stimulated)[26].  Moreover,  it  is  believed  that  in  increasing  ovarian
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Figure 4
Figure 4  Transvaginal gynecological ultrasound. Asterisks show complex paraovarian tumor, multilobed,
containing liquid and semiliquid, well defined, and with internal walls, suggesting hydrosalpinx. Doppler map of low
vascularization and Doppler fluxometry with normal resistances.
androgens (with accumulation of androstenedione and testosterone, which are not
transformed into  estrogen),  FSH receptor  genes  are  amplified,  with  a  resulting
follicular sensitization to follicular development stimulus. Letrozole is combined with
rFSH in patients expected to have poor response to hyperstimulation (as in this case,
as the patient already had a low baseline ovarian reserve due to her age). Regarding
the fact that increased estrogen levels may potentially be risky in hormone-dependent
breast cancer patients (they could stimulate breast tissue growth again),  recently
developed ovarian stimulation protocols with aromatase inhibitors seem to provide
safer ovarian stimulation with endogenous estrogen.
On the other hand, the patient had factors that favor pregnancy: she was a person
with strict healthy habits, she had a triple positive breast cancer (positive hormone
receptors and HER2 that made it more hormosensitive and more chemosensitive),
there was no metastasis present at diagnosis, and she had a very positive attitude
towards life. Regarding attitude, it is known that dispositional optimism is a predictor
of quality of life preservation in women with breast cancer[27], and it favors greater
adherence  to  treatment  and  better  patient  follow-up.  Moreover,  there  is  also  a
correlation between positive attitude and pregnancy success;  some studies  have
concluded that  being  pessimistic  may be  a  risk  factor  for  IVF treatment  failure,
independent of other factors that may negatively affect treatment outcomes of fertility
(such as age, for example)[28].
Another factor that favored a full-term pregnancy in this patient was that, despite
her gynecological history, she correctly prepared the endometrium. In accordance
with the endometrial preparation protocol for embryo transfer, for IVF in a natural
cycle the treatment started on the 1st-2nd d of menstruation with Progynova® 2 mg
every 8 h for 15 d. After these 2 wks, the patient underwent both ultrasound (to assess
thickness and appearance of the endometrium) and a blood test to check estrogen
levels. If everything was correct in these checks, Progesterone was added (two vaginal
ovules every 8 h), and after 3-4 d, embryo transfer performed (outpatient procedure
under  ultrasound  control).  Treatment  with  Progesterone  +  Progynova®  was
maintained until the pregnancy test and, in case of pregnancy, until week 11-12 of
pregnancy[29].
In general, the probability of natural pregnancy in a fertile woman is approximately
20%[30],  and it  decreases  as  female  age increases.  This  fertility  reduction is  more
pronounced from the middle of the third decade of life[31]. In addition, the chance of
giving birth after one IVF cycle is approximately 6%-10% in women ≥ 40 years old, as
we noted earlier.
To calculate an approximation of the probability of our patient’s having a full-term
gestation; several factors had to be considered. First, there was endometriosis and
surgery for it. According to some recent studies, the pregnancy rate after laparoscopic
surgery for endometriosis is about 55%. However, once pregnancy is established, the
prematurity risk is only slightly higher than it is for the general population, since
there are no significant differences either in spontaneous abortion rate or in other
maternal and neonatal complications[32]. Moreover, nowadays it is known that the
presence of endometriomas has no impact on clinical IVF outcomes, and that the
optimal time to perform IVF appears to be 7-25 mo after endometriosis surgery[33].
Regarding submucosal fibroids (which correspond to 5%-10% of uterine fibroids,
producing more symptoms than the other fibroid types, such as metrorrhagia and
infertility), myomectomy is the indicated therapeutic technique, and it is used more
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Figure 5
Figure 5  Type A embryo transferred to the patient.
frequently  in  women  with  symptomatic  myomas  and  future  fertility  desire.
Pregnancy rates following this surgery, both via laparoscopy and laparotomy, are in
the 50%-60% range[34]. However, myomectomy may not permanently eliminate the
symptoms, and it is associated with risks (post-operative adhesions, for example, can
negatively  affect  fertility)  and  surgical  complications.  Patients  who  undergo
myomectomy for submucosal fibroid resection have higher clinical pregnancy rates
compared to patients with non-operated myomas (43.3% vs 27.2%, respectively)[35].
Moreover,  IVF  pregnancy  rates  in  women who  undergo  a  salpingectomy for
hydrosalpinx are about 40%, and the risk of having an ectopic pregnancy in IVF in
patients who have been operated on is 2.2% (comparing with non-treated patients:
8.6%)[36].
In addition, we must also consider breast cancer and its adjuvant treatment with
chemotherapy and hormone therapy. Fertility preservation for breast-cancer patients
using unstimulated in vitro maturation followed by oocyte or embryo vitrification has
shown calculated pregnancy rates per vitrified oocyte and embryo of 3.8% and 8.1%,
respectively[37].  In some studies,  it  has been shown that,  after chemotherapy and
hormone therapy, the incidence of amenorrhea increases to 68%[1]. Up to 5% of women
suffer  from secondary  amenorrhea  during  their  lifetime;  that  is,  the  absence  of
menstrual period in a woman of reproductive age for ≥ 6 mo, for example, produced
by a common cause such as stress. The importance of this is that woman suffering
from secondary amenorrhea have greater difficulties becoming pregnant, although
this is not a cause of infertility itself, unless the period loss is evident or is not treated
for a long time. In fact, in 85% of cases, a simple change in diet or in lifestyle can
rebalance the hormonal system, permitting easy and healthy gestation.
It is not possible to make a statistical calculation of the overall probability of getting
pregnant (including birth of a live baby) by combining different probabilities of the
discussed  pathologies  suffered  by  the  patient,  because  data  sources  for  each
pathology are independent. Even so, this clinical case shows that despite the low
probabilities  of  successful  motherhood (due to  the  consecutive  accumulation of
gynecological and oncological pathologies), the patient eventually gave birth to a
healthy baby.
In summary, we have presented a special clinical case of full-term pregnancy and
successful exclusive breastfeeding during the first 9 mo of the baby’s life. This is of
interest given several factors (both positive and negative) discussed in this case report,
since the chances of patient pregnancy success were theoretically low. Currently, the
first  choice  for  premenopausal  breast  cancer  patients  is  adjuvant  therapy,  and
although cytotoxic drugs and/or hormone therapy can significantly reduce mortality,
questions  arise  regarding long-term toxicity,  such  as  menopause  induction  and
fertility deterioration, of these treatments. Thus, in these women it is essential to
propose  therapies  to  preserve  fertility  before  starting  potentially  gonadotoxic
treatment as well as to refer them early on to a specialized reproduction center if there
is a wish for a future pregnancy.
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Figure 6
Figure 6  Abdominal obstetric ultrasound. Dorso-posterior feed with first fetal position of a second trimester fetus.
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ARTICLE HIGHLIGHTS
Case characteristics
Full-term  pregnancy  success  in  a  43-year-old  woman  treated  with  chemotherapy  and
hormonotherapy for breast cancer who also had having several gynecological problems.
Clinical diagnosis
Endometriosis, ovarian cyst, hydrosalpinx, submucosal myomas, breast cancer, and in vitro
fertilization.
Differential diagnosis
Laparoscopy, lymphadenectomy, chemotherapy, radiotherapy, and hormonotherapy.
Laboratory diagnosis
Biopsy evidencing a human epidermal growth factor receptor 2-positive hormone-dependent
(80% estrogenic receptors, 70% progestational receptors) CD56 negative high grade invasive
ductal carcinoma.
Imaging diagnosis
Ultrasound and Doppler showing ovarian cystic tumors, hydrosalpinx, and breast cancer tumor.
Pathological diagnosis
Pathological  diagnosis  showed  a  pT1bpN1a,  stage  IIA  breast  cancer  tumor.  Diagnostic
hysteroscopy showed two small submucosal myomas.
Treatment
Chemotherapy  based  on  Epirubicin  and  Cyclophosphamide,  followed  by  Docetaxel  and
Trastuzumab; Hormonotherapy based on Tamoxifen followed by subcutaneous Trastuzumab;
Radiotherapy;  Oral  contraception  based on  Suavuret®  (Desogestrel  and EthinylEstradiol);
Uterine endometrium preparation based on Progynova® (equivalent to EstradiolValerate).
Related reports
The probability of natural pregnancy in a fertile woman is approximately 20%. With age and
health problems such as gynecological or/and oncological, this percentage drops significantly.
This case serves to maintain hope in women in a similar situation who wish for motherhood.
Term explanation
Successful pregnancy achieved (with healthy baby born) with only one in vitro fertilization
procedure, using a single vitrified embryo at age 39, and transferred at age 43.
Experiences and lessons
This is a special clinical case of a patient with theoretically low pregnancy success, probably due
to the consecutive accumulation of gynecological and oncological pathologies, who became
pregnant and delivered a full-term infant with adequate breastfeeding.
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